Clinical Trials on Alzheimer's Disease

Preliminary Program

Boston, November 1-4, 2017

LATE CALL FOR ABSTRACTS
September 1-15, 2017
www.ctad-alzheimer.com
Wednesday, November 1

4:00 – 4:30 p.m
Welcome from the Organizing Committee and CTAD Award for Lifetime Achievement in Alzheimer’s Disease Research

4:30 – 5:00 p.m
Keynote 1
The Evolution of Preclinical Alzheimer’s disease: Implications for Prevention Trials
Reisa Sperling, MD
Professor of Neurology, Harvard Medical School
Director, Center for Alzheimer Research and Treatment
Brigham and Women’s Hospital and Massachusetts General Hospital Memory Disorders Unit Boston, USA

5:00 – 6:00 p.m
Symposium 1
Importance of Serotonin in Alzheimer’s Disease Psychosis and the Potential Role of Pimavanserin
Moderator: Jeffrey Cummings, MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

1. Role of 5-HT2a Receptors in the Pharmacology of Alzheimer’s disease Psychosis
Stephen M. Stahl, MD, PhD\(^1\), Ethan S. Burstein, PhD\(^2\)
(1) University of California, San Diego, CA, USA ; (2) ACADIA Pharmaceuticals Inc., San Diego, CA, USA

2. Clinical Trial of Pimavanserin in Alzheimer’s disease Psychosis
Clive Ballard, MBChB, MRCPsych\(^1\), Carol Banister, MBChB, MRCPsych\(^2\), Jim Youakim, MD\(^3\), Bruce Coate, MPH\(^3\), Srdjan Stankovic, MD, MSPH\(^4\), on behalf of the ADP Investigators
(1) University of Exeter Medical School, Exeter, UK ; (2) King’s College, London, UK ; (3) ACADIA Pharmaceuticals Inc., San Diego, CA, USA

3. Review of Pimavanserin Clinical Results in the Context of Historical Alzheimer’s disease Psychosis Trials
Pierre N. Tariot, MD\(^1\), Randall Owen, MD\(^2\), Doral Fredericks, PharmD, MBA\(^3\)
(1) Banner Alzheimer’s Institute and University of Arizona College of Medicine, Phoenix, AZ, USA ; (2) ACADIA Pharmaceuticals Inc., San Diego, CA, USA
Thursday, November 2

8:30 – 10:00 a.m

Coffee Break and Poster Session

10:00 – 10:30 a.m

Oral Communications

OC1 - A Phase 2a Exploratory Endpoint Trial in Mild-Moderate Alzheimer’s Disease of LMI1A-3I-BH7 p75 neurotrophin receptor ligand.
Fratny M. Longo, MD, PhD; Manfred Windisch, PhD; Niels Andreassen, MD; Agneta Nordberg, MD, PhD
(1) Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, CA, USA; (2) NeuroSci, GmbH, Graz, Austria; (3) Department of Neurobiology, Karolinska Institute, Stockholm, Sweden; (4) Center for Alzheimer’s Research, Karolinska Institute, Stockholm, Sweden

OC2 - Tau Accumulation Observed using Repeated Tau PET Measures Predicts Cognitive Decline in Normal Elderly
Bernard Hanseew2, Beth Morrow2, Alex Becker1, Aaron Schultz1, Jorge Sepulcre1, Kathryn Papp1,2, Heidi Jacobs1, Jasmeen Chhatwai1,2, Dorene Rentz1,2, Reisa Sperling1,2, and Keith Johnson1,2,4
(1) Department of Radiology, Massachusetts General Hospital, Boston, MA, USA; (2) Department of Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium; (3) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; (4) Center for Alzheimer’s Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

OC3 - Clinical evaluation of 18F-PI-2620, a next generation TAU PET agent in subject with Alzheimer disease and progressive supranuclear PALSy
Andrew Stephens1, John Seibyl2, Andre Mueller1, Olivier Barret2, Mathias Berndt1, Jennifer Madonia2, David Aaligge5, Hanno Schiererstein1, Heiko Krosh1, Santiago Bullich1, Andrea Pfeifer1, Andreas Muhls1, Gilles Tamagnan1, Kenneth Marell1, Ludger Dinkelborg1
(1) Piramal Imaging, Berlin, Germany; (2) Molecular Neuroimaging, New Haven, USA; (3) AC Immune SA, Lausanne, Switzerland

OC4 - Optimizing the Preclinical Alzheimer’s Cognitive Composite (PACC) with Semantic Processing: The PACC 5
Kathryn V. Papp PhD2, Dorene M. Rentz PsyD2, Irina Orlovsky MA2, Reisa A. Sperling MD2, Elizabeth C. Morrow PhD2
(1) Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; (2) Department of Neurology, Massachusetts General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; (3) Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, USA

OC5 - Can IT Help with the Screening for Alzheimer’s Disease Trials? From EHR to Web-Based Cognitive Tests and e-Consent.
Michael W. Weiner, MD; Peter Schueeler, MD13, J. Wesson Ashford, MD, PhD14, Bruno Vellas, MD, PhD15
(1) UCSF, San Francisco, USA; (2) ICON, Langen, Germany; (3) University Duisburg-Essen, Germany; (4) Stanford/VA Alzheimer’s Disease and Aging Clinical Research Centers, CA, USA; (5) VA Palo Alto Health Care System, CA, USA; (6) Stanford University, CA, USA; (7) University Hospital’s Department of Internal Medicine and Clinical Gerontology, Toulouse, France; (8) Toulouse Gerantopole, Toulouse, France

OC6 - Amyloid Beta Oligomers in Alzheimer’s Disease: A Missing Piece of the Alzheimer’s Puzzle
Jeffrey Cummings MD; Sandrine Андрею MPH2; Aidan Power, MD1; Martin Tolar MD PHD2; Susan Abushatra MD2; Philip Scheltens MD, PHD2; Kaj Blennow MD PHD2; Petr Kocis PHD1; John A. Hey PHD1
(1) AbbVie Inc, North Chicago, IL, USA; (2) C2N Diagnostics LLC, Saint Louis, MO, USA; (3) Washington University, St. Louis, MO, USA; (4) Washington University, St. Louis, MO, USA; (5) University of Pennsylvania School of Medicine, Philadelphia, PA, USA; (6) VU University Medical Center, Amsterdam, Netherlands; (7) The Sahlgrenska Academy at University of Gothenburg, Malmö, Sweden

10:30 – 11:30 a.m

Oral Communications

OC7 - ABBV-BE12, a Humanized Anti-Tau Monoclonal Antibody for the Treatment of Early Alzheimer’s Disease: A 96-Week, Multiple Dose, Randomized, Double-Blind, Placebo-Controlled Phase II Study
Kumar Budur1, Hanh Florian1, Deli Wang1, Weining Robieson1, Holly Soares1, Joel B. Braunstein2, David M. Holtzman3, Randall J. Bateman1, Beatrice Rendenbach-Mueller,2, Nuno Mendonca1
(1) AbbVie Inc, North Chicago, IL, USA; (2) C2N Diagnostics LLC, Saint Louis, MO, USA; (3) Washington University, St. Louis, MO, USA; (4) AbbVie Deutschland GmbH & Co. Kg, Ludwigshafen, Germany

OC8 - Stratification of Pre-Symptomatic and Cognitively Normal Individuals using Polygenic Scoring
Maryam Shoir1, Richard Pither, PhD2; Valentina Escott-Price, PhD2; Simon M. Law2, PhD2; Harald Hampel, MD, PhD2; Simone Lista1, PhD2; Ribi Vandenbergh3, Isabelle Cleynen4; David Irwin1, MD2; Vivian Van Deelen1, MD2; Greg Davidson1, MD; Virginia M.-Y. Lee, PhD1; John O. Trojanowski, MD, PhD1; John Hardy, PhD2; DSC1
(1) UCL Institute of Neurology, London, United Kingdom; (2) Cygost Ltd, UK, Oxford, United Kingdom; (3) Cardiff University, Cardiff, United Kingdom; (4) Edith Cowan University, and Cooperative Research Centre for Neurodegenerative Diseases; (5) AXA Research Fund B & UPJMC Chair, Paris, France; (6) Klinische Universitatsklinik Tuebingen, Tuebingen, Germany; (7) Hospital of the University of Pennsylvania, Department of Neurology, University of Pennsylvania, Philadelphia; (8) Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia; (9) Ledcourt Associates, UK; (10) Centre for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia
OC9 - Objective Cognitive Decline in Preceding Years Relates to Self-Report on the Cognitive Function Index in the Harvard Aging Brain Study
Rebecca E. Amariglio PhD,1,2, Rachel F. Buckley PhD,3,4,5, Elizabeth C. Mormino PhD,2,3, Dylan R. Kirn MPH,3, Gad A. Marshall MD,4,5, Keith A. Johnson MD,1,2,3, Dorene M. Rentz PsyD,2,3, Reisa A. Sperling MD,1,2
(1) Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA ; (2) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA ; (3) Harvard Medical School, Boston, MA USA ; (4) Florey Institutes of Neuroscience and Mental Health, Melbourne, Australia ; (5) Melbourne School of Psychological Science, University of Melbourne, Australia

OC10 - The Generation Program: Evaluating CNP520 Efficacy in Preclinical Alzheimer’s Disease
Cristina Lopez Lopez, MD, PhD,1, Pierre N. Tariot, MD,2, Angelita Caputo, PhD,1, Fonda Liu, Pharm.D,1, Marie-Emmanuelle Riviere, PhD,1, Marie-Laure Rouzade-Dominguez, PhD,1, Ronald G. Thomas, PhD,1, Jessica B. Langbaum, PhD,2, Rob Lenz, MD, PhD,2, Eric M. Reiman, MD, PhD,1, Ana Graf, MD,1
(1) Novartis Pharma, Basel, Switzerland ; (2) Banner Alzheimer’s Institute, Phoenix, AZ, USA ; (3) University of California-San Diego, San Diego, CA, USA ; (4) Amgen, Thousand Oaks, CA, USA.

Symposium 2
CTAD 2017 Statistical Workshop: Estimands and Primary Analyses in AD Clinical Trials
Moderator: Hong Liu-Seifert Ph.D.
Eli Lilly and Company, Indianapolis, IN USA
Fabian Model Ph.D.
Roche, Basel, Switzerland
Paul Aisen M.D.
Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA

Lunch and Poster Session

1:30 – 2:30 p.m
Late Breaking Oral Communications

2:30 – 3:00 p.m
Keynote 2
From Academy to Industry: Perspectives for Drug Trials in AD
Rachelle Doody, MD, PhD
Global Head of Neurodegeneration PD Neuroscience, F. Hoffmann-La Roche, Basel, Switzerland

3:00 – 4:00 p.m
Late Breaking Oral Communications

4:00 – 4:30 p.m
Coffee Break and Poster Session

4:30 – 5:30 p.m
Symposium 3
EPOCH Trial of the BACE1 Inhibitor Verubecestat for Mild-to-Moderate Alzheimer’s Disease
Michael Egan, MD,1 James Kost, PhD,2 Pierre N. Tariot, MD,2 Paul S Aisen, MD,2 Jeffrey L. Cummings, MD, ScD,4 Bruno Vellas, MD PhD,5 Yumi Mutchi, MD,6 Tiffini Voss, MD,2 Christine Furrer, MS, Erin Mahoney, MS,2, Rith Vandenberghe, MD, PhD,2 Yi Mo, PhD,1, David Michelson, MD,1
(1) Merck & Co., Inc., Kenilworth, NJ, USA; (2) Banner Alzheimer’s Institute, Phoenix, AZ, USA; (3) University of Southern California, San Diego, CA, USA; (4) Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA; (5) Gerontopole, INSERM U 1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France; (6) University Hospital of Leuven, Leuven, Belgium
Coffee Break and Poster Session

Keynote 3
Genetic Aspects In Clinical Trials
John Hardy, Reta Lila Weston Institute of Neurological Studies, University College London, London UK

Oral Communications

OC17 - Cognitive Run-In Periods for Amyloid-Positive Enriched Secondary Prevention Trials.
Andrew J. Aschenbrenner, PhD, Jason Hassenstab, PhD, Eric McDade, DO, Guoqiao Wang, PhD, Tammie L.S. Benzinger, MD, PhD, Randall J. Bateman, MD, & John C. Morris, MD.
(1) Department of Neurology, Washington University in St. Louis; (2) Department of Psychological and Brain Sciences, Washington University in St. Louis; (3) Department of Biostatistics, Washington University in St. Louis; (4) Department of Radiology, Washington University in St. Louis.
Friday, November 3

**Lunch and Poster Session**

12:30 – 1:30 p.m

OC18 - Eigen Combinations of Cognition and Biomarkers to Minimize the Sample Sizes in Prevention Trials on Alzheimer Disease

Chenguang Xiao1,2,3,4, PhD, Anne M. Fagan2,3,5, PhD, Tambrie Benzinger1,6, PhD, Jason Hassenstab1,2,3, PhD, John C. Morris1,2, MD, Randall J. Bateman1,2,3, MD.

(1) Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA; (2) Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; (3) Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; (4) Department of Mathematics, Washington University School of Medicine, St. Louis, MO, USA; (5) The Dominantly Inherited Alzheimer Network, Washington University School of Medicine, St. Louis, MO, USA

OC19 - The Alzheimer’s Prevention Registry and GeneMatch: Accelerating Recruitment and Enrollment into Alzheimer’s Studies

Jessica L. Langbaum, PhD, Nellie High, MD, David Gordon, MD, Jodie Nichols, MD, Trisha Walsh, MD, Eric M. Reiman, MD, Pierre N. Tariot, MD

(1) Banner Alzheimer’s Institute, Phoenix, AZ, USA

OC20 - An Examination of Rate of Decline as an Alternative to Change from Baseline

Howard Mackey, PhD, Nan Hu, PhD, Michael Ahmad, MSc, Yinghua Chen, MSc, Pierre Tariot, MD, Eric Reiman, MD, Francisco Lopez, MD, Kewei Chen, PhD, Ronald Thomas, PhD.

(1) Genentech, Inc., South San Francisco, CA, USA; (2) Banner Alzheimer’s Institute, Phoenix, AZ, USA; (3) Universidad de Antioquia, Medellin, Colombia; (4) UC San Diego Department of Neurosciences, CA, USA

OC21 - The Safety and Efficacy of Edoneric (T-817) in Patients with Mild to moderate Alzheimer’s Disease

Lon S. Schneider, MD, MD1, Ronald G. Thomas, PhD2, James Brewer, MD, Suzanne Hendrix, PhD, Robert Rissman, PhD, David Salmon, PhD, Hiroshi Kobayashi, Howard Feldman, MD, for the ADCS TCAD group

(1) Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; (2) University of California, San Diego, CA, USA

OC22 - Safety of and Tolerability of Gantenerumab in the Open-Label Extension of SCarlet RoAD Trial, a Global Study in Patients with Prodromal Disease

Mirjana Andjelkovic, PhD

(1) Hoffman La Roche, Basel, Switzerland; (2) Roche Products Limited, Welwyn, UK

OC18 - Rationale, Design and Progress of the 3 Active Alzheimer’s Prevention Initiative Trials

Pierre Tariot, MD, Banner Alzheimer’s Institute, University of Arizona College of Medicine, Phoenix, AZ, USA

1:30 – 3:30 p.m Late Breaking Oral Communications

**Oral Communications**

3:30 – 4:00 p.m

OC23 - The European Prevention of Alzheimer’s Dementia (EPAD) and Amyloid Imaging for Prevention of Alzheimer’s Dementia (AMYPAD) Projects: Cohort Readiness for the Adaptive Clinical Trial Platform.

Andrew Sattin, MD1, Craig Ritchie MD PhD2, Mila Kivipelto MD PhD3, Alina Soloman MD PhD4, Brian Tom PhD5, Jose Luis Malineu MD PhD6, Scott Berry PhD7, Frederik Barthof MD PhD8, Gill Farr PhD9

(1) Eisai Pharmaceuticals, USA; (2) Centre for Dementia Prevention, University of Edinburgh, UK; (3) Ageing Research Centre, Karolinska Institute, Sweden; (4) MRC Biostatistics Unit, University of Cambridge, UK; (5) Barcelona Beta Brain Research Centre, Spain; (6) Berry Consultants Ltd, Texas, USA; (7) VU University Medical Centre, Amsterdam, The Netherlands; (8) General Electric, Amersham, UK

OC24 - Towards a New Biomarker Battery for Drug Development in Alzheimer’s Disease

Olivier Blin, MD, PhD1, Régis Bordet MD PhD2, Jill Richardson PhD3, Pierre Payoux MD PhD4, Claudio Babiloni MD PhD5, David Barnes-Fat MD PhD6, Catherine Cassé-Perot PhD7, Giovanni Frisoni MD PhD8

(1) University of Aix-Marseille; (2) University of Lille; (3) GSK; (4) University of Toulouse; (5) University of Roma; (6) University of Barcelona; (7) University of Geneva

**Coffee Break and Poster Session**

4:00 – 4:30 p.m

4:30 – 5:00 p.m

Keynote 4

Rationale, Design and Progress of the 3 Active Alzheimer’s Prevention Initiative Trials

Pierre Tariot, MD, Banner Alzheimer’s Institute, University of Arizona College of Medicine, Phoenix, AZ, USA

5:00 – 6:00 p.m

Symposium 4

Results from the Phase 3 MINDSET STUDY: A Global, Double-Blind, Placebo-Controlled Study of Intepirdine in Mild-to-Moderate Alzheimer’s Disease

- Presentation 1: Analysis of primary efficacy and safety results
- Presentation 2: Analysis of secondary endpoints and measures of clinical meaningfulness
- Discussion and Q&A

CTAD 2017
Saturday, November 4

08:30 – 10:00 a.m Oral Communications

**OC25 - ORY-2001 Rationale in Mild to moderate Alzheimer’s Disease**
Roger Bullock, MD1, Cesar Molinero MD,PhD2, Tamara Maes PhD1
(1) Oryion Genomics S.A. Barcelona Spain

**OC26 - Plasma Amyloid Levels within the Alzheimer’s Process and Correlations with Central Biomarkers**
Olivier Hanon, MD, PhD1, Jean-Sébastien Vidal MD, PhD1, Sylvain Lehmann MD, PhD2, Stéphanie Bombois MD, PhD3, Bernadette Allingquant MD4, Marie Godin Msc1, Patrick Gelé MD5, Christine Delmaire MD6, Frederic Blanc MD7, PhD, S Schraen MD8, Audrey Gabelle MD9 and the BALTAZAR study group.
(1) Department of Gerontology, Bruco Hospital, Paris, France ; (2) Laboratoire de Photorimie Clinique, Department of Biochemistry, Saint Eloi Hospital, INERIL, Inserm U1063, France ; (3) CMRR de Lille, Department of Neurology, Lille, France ; (4) Centre de Psychiatrie et Neurosciences, Université Paris Descartes, Paris, France ; (5) University of Lille Nord de France, Department of Biology and Pathology, Lille University Hospital, INSERM UMR 172, 59037 Lille, France ; (6) CMRR de Strasbourg, Department of Gerontology, Strasbourg, France ; (7) CMRR de Montpellier, Department of Neurology, Inserm U1063, Montpellier, France.

**OC27 - Online Clinical Research: Updates and Insights from the Brain Health Registry**
Shannon Finley, MA1, Diana Truran1, Dereth Flenihen2,3, Juliet Fochtler1, Rachel L. Nosheny PhD1,3, Monica Camacho1, R Scott Machin PhD2 and Michael W Weiner MD3
(1) Center for Imaging of Neuodegenerative Diseases, San Francisco; Veterans Administration Medical Center, San Francisco, CA, USA ; (2) UCSF Department of Psychiatry, San Francisco, CA, USA ; (3) UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA, USA.

**OC28 - BPN14770 Phosphodiesterase-4D Negative Allosteric Modulator for Alzheimer’s Dementia: Preclinical, PET Imaging and Human Phase I Results**
Mark Gurney, PhD1, Chong Zhang PhD2, Ying Yu PhD1, James O’Donnell PhD1, Masahiro Fujita MD, PhD1,2, Robert Innis MD, PhD1, Victor Pile PhD2, Sanjay Telu PhD2 and Scott Reines, MD, PhD1
(1) TerraDiscovery Partners, Inc. Grand Rapids, MI, USA ; (2) School of Pharmacy and Pharmacological Sciences, University at Buffalo, Buffalo, NY, USA ; (3) National Institute of Mental Health, Bethesda, MD, USA

**OC29 - Amyloid Beta Stable Isolatn Labels Kinetics and Concentrations of Human Plasma Detect CNS Amyloidosis**
Vitaliy Ovod MS1, Kara Ramsey, BS2, James Bollinger PhD2, Kwasi Mawuenyega, PhD2, Terry Hfits, BA1, Theresa Schneider1, Thomas Kasten, PhD1, Wendy Sigurdson, RN1, Melissa Sullivan, MS1, Tamara Donahue1, RN, Karinna Paumier, PhD1, David Holtzman, MD2-4, John Morris, MD4, Tammie Benzing MD, PhD4-6, Anne Fagan PhD4-7, Bruce Patterson, PhD8, and Randall Bateman, MD3,9
(1) VBI Chem Therapeutics; (2) University of Arkansas; (3) Washington University in Saint Louis; (4) National Institute on Aging; (5) National Institute of Biomedical Imaging and Bioengineering; (6) University of Maryland School of Medicine; (7) California Institute for Environmental Control; (8) University of California, San Diego; (9) University of California, San Francisco.

10:00 – 10:30 a.m Coffee Break and Poster Session

10:30 – 11:30 a.m Late Breaking Oral Communications

11:30 – 12:30 a.m Symposium 5

**Synaptic and Network Dysfunction in Alzheimer’s Disease (AD): Translational Insights and Therapeutic Opportunities**
Moderator : Arjen Brussard, PhD, Amsterdam Neuroscience, VU Medical Center, Amsterdam, Netherlands

1. Targeting unfolded protein response and synaptic dysfunction to enhance memory function and prevent neurodegeneration
Giovanna Malucci, MD PhD1,2,3
(1) Dept. of Clinical Neurosciences, University of Cambridge, Cambridge, UK ; (2) UK Dementia Research Institute at University of Cambridge, Cambridge, UK ; (3) MRC Toxicology Unit, Leicester, UK

2. Modulation of synaptic and network activity and endocytosis with light ficher therapy reduces amyloid pathology in mouse model of AD
Li-Hueh Tsai, PhD1
(1) Picower Institute of Memory and Learning, Massachusetts Institute of Technology, Cambridge MA, USA

3. Preclinical rationale and early clinical results of p38 alpha kinase inhibition to reverse hippocampal synaptic dysfunction
John Alam, MD1
(1) EIP Pharma, LLC, Cambridge MA, USA
**Saturday, November 4**

**Lunch and Poster Presentation**

**Late Breaking Oral Communications**

**Early Oral Communications**

**OC31 - A Phase Ib, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 (abeotaxane) in Patients with Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy; or the Secondary Tauopathy, Alzheimer’s Disease.**

Peter Ljubenkov, MD; Zachary Miller, MD; Richard Tsai, MD, MBA; Mary Koestler, RN, PhD; Julio Rojas, MD, PhD; Peter Lubbenkov, MD; Howie Rosen, MD; Gil Rabinovic, MD; Anne Fagan-Niven, PhD; Yann Cobigo, PhD; June Jung, PhD; Phi Luong, BS; Emmeline Chuu, BA; Ryan Powers, BA; Paige Mumford, BA; Bruce Miller, MD; Erik Roberson, MD

(1) Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA; (2) Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA; (3) Department of Neuroscience, University of Alabama School of Medicine, Birmingham, AL, USA

**OC32 - Rapid, Remote, and Repeatable: Smartphone-Based “Burst” Cognitive Assessments for Global AD Prevention Trials.**

Jason Hassenberg, PhD; Andrew J. Aschenbrenner, PhD; Martin J. Sliwinski, PhD; Eric McCade, DO; Yen Ying Lim, PhD; Paul Maruff, PhD; David A. Balota, PhD; John C. Morris, MD; Randall J. Bateman, MD, & The Dominantly Inherited Alzheimer Network-Trials Unit.

(1) Department of Psychology, Washington University School of Medicine, St. Louis, MO USA; (2) Department of Psychological & Brain Sciences, Washington University, St. Louis, MO USA; (3) The Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), Washington University School of Medicine, St. Louis, MO USA; (4) Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO USA; (5) Department of Human Development and Family Studies, Pennsylvania State University, State College, PA USA; (6) The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia; (7) Cogstate Ltd, Melbourne, Victoria, Australia

**OC33 - Associating Cognitive Functioning Profiles with Amyloid Status in ADNI2, with Implications for Adaptive Screening for Amyloidosis.**

Sarah J Carr PhD; Judith Jaeger PhD; Nancy Maserejian ScD; Ahmed Enayatallah; Alan Lerner; Yanming Wang; Sheng Yang; Wenting Wang; Shijia Biang; Curtis Tatsuoka PhD and for the Alzheimer’s Disease Neuroimaging Initiative*

(1) Department of Neurology, Case Western Reserve University, Cleveland, OH, USA; (2) Cognitive Metrics, DE USA; (3) Department of Psychology and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY USA; (4) Biogen, Cambridge, MA, USA; (5) Neurological Institute, University Hospitals Case Medical Center, Beachwood, OH, USA; (6) Department of Radiology, Case Western Reserve University, Cleveland, OH USA; (7) Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH USA

**OC34 - Alzheimer’s Disease Dementia and the Long-Term Impact on Caregiver Burden – 36-Month results from GERAS.**

Catherine Reed, PhD; Mark Belger, BSc; J. Scott Andrews, PharmD; Antje Tochhorn-Heidenreich, MSc.

(1) Eli Lilly and Company Limited, Windlesham, UK; (2) Eli Lilly and Company, Indianapolis, IN, USA

**OC35 - Neuroprotective Effect of a New Photobiomodulation Technique against Amyloid Aβ25-35 Peptide-Induced Toxicity in Mice.**

Guillaume J. Blivet, MS; Johann Meunier, PhD; Francois J. Roman, PhD; Jacques Touchon, MD, PhD

(1) REGENEPIE SAS, Montpellier, France; (2) Amlygen SAS, Montpellier-sur-her, France; (3) INSERM U801, Montpellier, France

**OC36 - Investigational New Alzheimer’s Drug Tricaprilin: Results of a Phase 3 Study in Mild-to-Moderate Alzheimer’s Disease Patients.**

Samuel Henderson, PhD; Michael Gold, MD; Judith Walker, MD; Sabrina Greer; Janet Vogel; Aaron Shenhin

(1) Accera Inc, Boulder, CO, USA; (2) PPD Inc, Wilmington, NC, USA

**OC37 - Characterization of the selective in vivo and in vitro binding properties of crenezumab: insights into crenezumab’s unique mechanism of action.**

William J. Meilandt; Janice A. Maloney; Jose Imperico; Travis W. Bainbridge; Milhe Reichelt; Danielle Mandlitan; Yannai Lu; James A. Ernst; Reina N. Fujii; Javinder K. Atwal

(1) Department of Neuroscience, Genentech, South San Francisco, CA, USA; (2) Department of Protein Sciences, Genentech, South San Francisco, CA, USA; (3) Department of Research Pathology, Genentech, South San Francisco, CA, USA; (4) Department of Preclinical and Translational Pharmacology, Genentech, South San Francisco, CA, USA; (5) Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, CA, USA; (6) Department of Safety Assessment, Genentech, South San Francisco, CA, USA

**OC38 - Prevention of Alzheimer’s Disease: Trajectories of Amyloid and the Effect of Abeta Peptide Immunization.**

Jason Hassenstab, PhD; Andrew J. Aschenbrenner, PhD; Martin J. Sliwinski, PhD; Eric McCade, DO; Yen Ying Lim, PhD; Paul Maruff, PhD; David A. Balota, PhD; John C. Morris, MD; Randall J. Bateman, MD, & The Dominantly Inherited Alzheimer Network-Trials Unit.

(1) Department of Neurology, Case Western Reserve University, Cleveland, OH, USA; (2) CognitionMetrics, DE USA; (3) Department of Psychological & Brain Sciences, Washington University School of Medicine, St. Louis, MO USA; (4) Biogen, Cambridge, MA, USA; (5) Department of Radiology, Case Western Reserve University, Cleveland, OH USA; (6) Department of Tariology, Case Western Reserve University, Cleveland, OH USA; (7) Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH USA

**OC39 - Moderate to Severe Alzheimer’s Disease: Insights into the Timing of Multiple Antibodies.**

Jason Hassenstab, PhD; Andrew J. Aschenbrenner, PhD; Martin J. Sliwinski, PhD; Eric McCade, DO; Yen Ying Lim, PhD; Paul Maruff, PhD; David A. Balota, PhD; John C. Morris, MD; Randall J. Bateman, MD, & The Dominantly Inherited Alzheimer Network-Trials Unit.

(1) Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA; (2) Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA; (3) Department of Neurology, University of Alabama School of Medicine, Birmingham, AL, USA

**OC40 - Memory and Aging Center: Department of Neurology, University of California, San Francisco, CA, USA; (2) Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA; (3) Department of Neuroscience, University of Alabama School of Medicine, Birmingham, AL, USA

**Closing Session**

4:15 – 4:30 p.m.